A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-911 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs SUVN 911 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suven Life Sciences
- 25 May 2017 According to a Suven Life Sciences media release, the topline results from this study are expected in the quarter first quarter of 2018.
- 25 May 2017 According to a Suven Life Sciences media release, the company has done first dosing in this study.
- 13 May 2017 Status changed from planning to recruiting.